Stock RZLT REZOLUTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Rezolute, Inc.

Equities

RZLT

US76200L3096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
4.03 USD -2.89% Intraday chart for Rezolute, Inc. +13.20% +306.05%
May. 22 Traders Cautious Ahead of Fed Minutes, Nvidia Earnings, Stifling US Equity Futures Pre-Bell MT
May. 22 Top Premarket Gainers MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Rezolute to Participate in the Jefferies Global Healthcare Conference
Traders Cautious Ahead of Fed Minutes, Nvidia Earnings, Stifling US Equity Futures Pre-Bell
Top Premarket Gainers
Rezolute : Corporate Presentation – May 2024
Transcript : Rezolute, Inc. - Special Call
Rezolute Reports Positive Topline Results in Study of Diabetic Macular Edema Treatment; Shares Surge After Hours
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
Rezolute, Inc. Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema
Transcript : Rezolute, Inc. - Shareholder/Analyst Call
Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
REZOLUTE, INC. - PHASE 2 RIZE STUDY SUB-ANALYSES TO BE PRESENTED AT THE 2024 PEDIATRIC ENDOCRINE SOCIETY ANNUAL MEETING
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
JonesTrading Starts Rezolute With Buy Rating, $10 Price Target
REZOLUTE REPORTS VALIDATION OF THE POTENTIAL USE OF RZ358 FOR TREATMENT OF NON-ISLET CELL TUMOR HYPOGLYCEMIA
Rezolute : Corporate Presentation – March 2024
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RZLT Stock
  4. News Rezolute, Inc.
  5. Other languages